Abstract: Insomnia disorder is present in as much as 30% of the general adult population. Given the significant adverse effects of pharmacotherapy, cognitive behavioral therapy (CBT) has been found to be an effective alternative in individuals with insomnia. CBT for insomnia (CBTi) encompasses sleep hygiene, stimulus control, sleep restriction, cognitive therapy, and relaxation training. In this article we review evidence that establishes CBTi as a useful treatment affecting remission, sleep onset latency, wakefulness after sleep, sleep efficiency, and sleep quality in adults with insomnia to include older adults and adolescents. In addition, we briefly highlight various CBTi delivery methods as well as barriers to accessing this safe and effective therapy.
T hirty percent of the general population complains of at least one symptom of insomnia, including trouble falling asleep, staying asleep, or early awakening. 1 After applying narrower criteria from both the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition or the International Classification of Sleep Disorders, 3rd Edition, approximately 10% of the population meets the criteria for insomnia disorder, with half of these individuals experiencing a chronic course. 1, 2 The risk factors for insomnia include lower socioeconomic status, female sex, older age, African American race, comorbid depression/psychiatric disorders, and shift work. [1] [2] [3] Furthermore, insomnia often coexists with other conditions, including malignancy, chronic pain, cardiopulmonary disease, and substance abuse. [1] [2] [3] Both the economic and health effects of chronic insomnia are significant. The incidence of diabetes mellitus, coronary artery disease, hypertension, and the metabolic syndrome are higher in patients with chronic insomnia. 4 Absenteeism and tardiness are more prevalent in employees with insomnia. 4 Individuals with chronic insomnia have higher healthcare expenditures than their well-rested counterparts. 1, 4 Cognitive behavioral therapy for insomnia (CBTi) offers an attractive alternative to the long-term efficacy and safety concerns associated with sedative-hypnotics and the adverse effects of other commonly used sleep medications. CBTi uses several components, including sleep hygiene (SH), stimulus control (SC), sleep restriction (SR), cognitive therapy, and relaxation training (RT). 3, 5 We present the evidence supporting the effectiveness of CBTi in adults, adolescents, and older adults; some potential options for CBTi implementation in primary care; and alternatives and relative contraindications to its use in patients with various comorbidities.
CBTi Versus Control
CBTi has established itself as an effective treatment for insomnia in a multitude of scenarios; however, researchers still raise questions about ability of CBTi to improve insomnia. How much does CBTi improve insomnia compared with medications? How long do the effects of CBTi last?
A clinical guideline based on a systematic review of randomized controlled trials (RCTs) published from 2004 through 2015 concluded that there is "moderate quality evidence that CBT-I [CBTi in the present article] improved remission, treatment response, sleep onset latency (SOL), wake after sleep onset (WASO), sleep efficiency (SE), and sleep quality (SQ) in the general (adult) population" 6 (Table 1) . It is worth noting that there were few adverse effects associated with CBTi, whereas the adverse effects of drug therapy include daytime drowsiness, dizziness, memory impairment, myalgia, hallucination, mood alterations, dry mouth, bad taste in the mouth, and risk of fall or fracture. 6 Insufficient evidence was found in relation to global sleep outcomes for interventions such as SR, SC, RT, brief behavioral therapy, benzodiazepines, melatonin, trazodone, and alternative therapies such as acupuncture and Chinese herbal medicine.
6 Table 2 contains explanations of these alternative cognitive/behavioral interventions.
A comparative effectiveness review using 18 RCTs (N = 1842) prepared for the Agency for Healthcare Research and Quality provided data specific to CBTi efficacy. 7 A pooled analysis from four small trials within this review (n = 179) revealed moderate-strength evidence that remission was 3 times more likely in the general adult population with CBTi when compared with passive controls (risk ratio 2.95; 95% confidence interval [CI] 1.78-4.87; number needed to treat, 2). Remission was defined as an Insomnia Severity Index (ISI) score <7 or a Pittsburgh Sleep Quality Index score <5. Pooled data from this review demonstrated a 5-point decrease in ISI scores (−5.15, 95% CI−7.13 to −3.16, n = 345) when CBTi was compared with waitlist/no treatment in adult patients studied for <6 months. In addition, a 2-point reduction in Pittsburgh Sleep Quality Index scores (−2.10, 95% CI −2.87 to −1.34, n = 580) was noted in adult patients treated with CBTi when compared with passive controls studied for <6 months. In relation to specific sleep outcomes, pooled data in this review also demonstrated a 12-minute reduction in SOL (−12.70, 95% CI −18.23 to −7.18, n = 1246), a 14-minute increase in total sleep time (TST; 14.24, 95% CI 2.08-26.39, n = 1233) and mean WASO of 22 fewer minutes (−22.33, 95% CI −37.44 to −7.21, n = 832) when CBTi was compared with passive controls in adults. Rates of withdrawal from studies or loss to follow-up were similar between treated groups and controls, suggesting that CBTi had no significant adverse effects.
A 2014 meta-analysis studied the effectiveness of group CBTi in 608 adult patients with mixed insomnia types. 8 Because of the heterogeneity of the variables analyzed, the authors could report only that CBTi had an effect size on SE of 1.13 (95% CI 0.70-1.56) when compared with placebo and that the effect size on SQ was 0.85 (95% CI 0.57-1.14) in comparison to placebo. Effect sizes of ≥0.80 were considered large. Although these numerical data cannot be translated to individual care, they do suggest that SE and SQ improve in populations treated with group CBTi.
Another 2015 systematic review and meta-analysis of CBTi including 1162 adult patients with chronic insomnia without comorbidities reviewed 20 RCTs comparing CBTi with inactive treatments. 3 The pooled data are summarized in Table 3 and are based on patient sleep diaries. The primary differences shown are that CBTi-treated patients spent one less hour awake, fell asleep more 
CBTi Versus Pharmacotherapy
A meta-analysis of pharmacotherapy versus CBT for primary insomnia was published in 2002. 9 Twenty-one studies including 470 adult patients compared different drugs (benzodiazepines, zolpidem, and zopiclone) and different CBT techniques (SR, SC, or both) while measuring multiple sleep outcomes (SOL, number of awakenings, WASO, TST, and SQ rating). The mean duration of drug therapy was 2 weeks, whereas the mean CBT treatment spanned 5 weeks. Overall, SOL was the only statistically different outcome between interventions, with CBT having a better reduction in sleep latency (43% vs 30% reduction; weighted effect size 0.45; 95% CI 0.17-1.04). All other outcomes improved in both groups in a nonsignificant fashion. The similarity in the effect size of sleep improvement indicates that CBTi should be considered equally efficacious when compared with benzodiazepines, with fewer adverse effects.
A small 2004 RCT (N = 63) compared CBTi, zolpidem, combined therapy, and placebo during a 6-week treatment period in middle-aged adults with chronic sleep-onset insomnia. 10 Exclusion criteria included comorbid psychiatric disorders, sleep apnea, periodic limb movement disorders, and pregnancy/breastfeeding. SOL in CBTi and combination groups improved compared with zolpidem alone or placebo at 2 weeks posttreatment (52% reduction in both CBTi and combination vs 17% and 14% reduction, respectively, P < 0.02). More people also achieved normal SOL, defined as <30 minutes, in the CBTi group than placebo and zolpidem groups (57% vs 14% and 15%, respectively, P = 0.05). SE also improved with CBTi to a greater degree when compared with zolpidem (17% vs 7%, P = 0.007). There was no significant difference between groups achieving normal SE (≥85%) or TST. Only SOL and SE were studied out to 1 year. The 1-year follow-up data only compared CBTi with combination participants, because a significant number of pharmacotherapy and placebo-arm patients changed treatments because of dissatisfaction with their initial therapy. After 12 months, there was no difference in SOL and SE for the CBTi or combination-arm patients when compared with initial posttreatment measurements.
The above studies indicate that CBTi improves insomnia as effectively as or better than medications without the harmful adverse effects associated with sedative-hypnotics. Although CBTi is equal to medications in efficacy, it is difficult for patients to access this therapy. Lack of trained providers within primary care settings, time efficiency, and cost limit CBTi implementation.
Older Adults
Adults older than 65 years have twice the rate of insomnia of younger adults. 11 Treating insomnia effectively in older people is paramount because they are at an increased risk for falls, which have high rates of morbidity and mortality. 12 Moreover, sedative-hypnotic medications used to treat insomnia have been shown to increase fall risk in older patients by 22%. 13 Given these findings, effective nonpharmacologic treatments for insomnia can reduce this associated morbidity and mortality.
The aforementioned Agency for Healthcare Research and Quality meta-analysis 7 found that CBTi across several delivery modalities improves both global and individual sleep outcomes (SOL, WASO, and SE) when compared with passive controls among older adults with insomnia. Pooled data of post-CBTi ISI scores, when compared with waitlist patients (N = 138 older adults), revealed mean reductions of 3.6 (95% CI 2.13-5.07) immediately after treatment, 2.1 (95% CI 0.55-3.65) at 3 months, and 3.3 (95% CI 1.36-5.24) at 6 months. Notably, the mean difference did not reach the minimum clinically significant difference of 7 points. Statistically significant reductions in validated insomnia scale scores were noted up to 16 months after CBTi treatment when compared with placebo or sham; however, the clinical significance of these reductions is unclear. In relation to specific sleep parameters, SOL was reduced by a mean of 9.98 minutes (95% CI −16.48 to −3.48) in a study comparing CBTi to placebo/sham or waitlist in 191 older adults studied up to 6 months. WASO was reduced by a mean of 26.96 minutes (95% CI −35.73 to −18.19) in pooled data of 220 older adults who received CBTi when compared with placebo/sham or waitlist. SE was increased by 8% in older adults studied out to 2 years. TST did not increase significantly with CBTi in these patients after 2 years posttreatment.
Studies have been performed using CBTi alone as well as in combination with hypnotic medications. CBTi in hypnoticsdependent patients instructed to remain on their medication was associated with significant improvement in several sleep variables. 14, 15 Another combination therapy study revealed improved remission rates in patients who tapered off pharmacotherapy as compared with patients who remained on medication after completion of CBTi. 16 The implementation of CBTi in older adults is fundamentally similar to that in younger adults with some potential modifications. SC typically requires the wakeful patient to leave the bed or bedroom when unable to fall back asleep quickly during the night. This recommendation should be altered for patients at increased risk of falls, requiring instead that the patient remain in bed while doing a relaxing activity such as reading or doing crossword puzzles, until sleepiness returns. Another component of CBTi often modified for older adults is the avoidance of napping. Napping is an adaptive behavior for many of these individuals to mitigate fatigue. Allowing time-limited (≤60 minutes) napping in the early afternoon also may allow for postponement of bedtime, the latter being one SC measure.
11 Napping has been shown to improve cognitive performance in some studies of older adults. [17] [18] [19] Relaxation-based interventions, including contraction of muscles alternating with relaxation, may be problematic for physically frail or older adults with musculoskeletal pain. Eliminating the contraction phase and focusing on muscle relaxation may reduce the discomfort and risk of muscle spasm. 20 Because RT may be the least effective behavioral intervention, 21 the practitioner may choose to recommend this modality in select patients or have them focus on the guided imagery and paced breathing components of RT.
The specific contribution of the cognitive therapy component of CBTi has not been studied well in older adults. Patients with cognitive impairment may be less responsive to these components. Data do support the efficacy of CBTi in the nursing facility setting 22 and in community-dwelling patients with Alzheimer disease. 23 Interventions in the latter study included SH, increased activity, and light therapy. SH as monotherapy has limited efficacy data, but often it is the logical starting point in older adults.
Insomnia in older adults often is compounded by comorbid conditions and the medications used to treat those conditions. Comorbid chronic pain and insomnia are highly prevalent, with 60% of people with arthritis in the United States reporting nocturnal pain. 24 Depression and anxiety also are frequently comorbid with insomnia. The relation may be bidirectional because individuals with insomnia have a higher risk of developing anxiety or depression and vice versa. 25 Although not focusing on older patients, several studies have shown the benefit of CBTi when insomnia is comorbid with depression, 26 cancer, 27 chronic pain, 28 and osteoarthritis. 29 Effective treatment of the comorbid medical or psychiatric disorder aids the effectiveness of insomnia treatment.
Adolescents
The adolescent period has no less of a proclivity for insomnia than other age groups. Hormonal changes, poor sleep schedules, and poor SH account for this phenomenon, making CBTi an attractive treatment option and sustainable alternative to medication. Unfortunately, CBTi has not been studied thoroughly in this population. A small cohort with an average age of 14.6 years (N = 26) in the Netherlands was studied comparing group CBTi with Internet-delivered CBTi. 30 This study demonstrated increased SE (Cohen d effect size 0.69 [medium effect], P < 0.001), decreased SOL (Cohen d effect size −0.97 [large effect], P < 0.001), and decreased WASO (Cohen d effect size −0.22 [small effect], P = 0.06) in both groups after the 6-week intervention and 2-month follow-up evaluation. TST and time in bed were not significantly changed from baseline. Another small randomized trial (N = 34, average age 19.7 years) showed similar improvement in SE, SOL, WASO, as well as improved sleep/ life quality when compared with waitlist controls 31 (Table 4) . Larger studies are needed to validate the effectiveness of CBTi in adolescents.
CBTi in Comorbid Conditions
A 2015 meta-analysis reviewed the utility of CBTi in patients with comorbid psychiatric and medical conditions. 32 Thirtyseven studies published between 1996 and 2014 were analyzed and involved 2189 adult patients. Comorbid conditions included alcohol dependence, breast cancer, hearing impairment, chronic obstructive pulmonary disease, Parkinson disease, osteoarthritis, depression, posttraumatic stress disorder, chronic pain, fatigue, sleep apnea, overall mood, and anxiety. A total of 36% of patients who received CBTi were in remission from insomnia compared with only 17% in the control or comparison groups. The effect sizes for SE, SOL, and WASO were medium to large when comparing pre-and posttreatment values and were similar to studies investigating CBTi in primary insomnia alone. In addition, SE and SQ revealed medium effect sizes favoring CBTi over control at both 3 and 12 months posttreatment. Interestingly, treating insomnia with CBTi also improved the symptoms of patients' comorbid disease, mood, and functionality. The symptoms associated with psychiatric disorders improved after CBTi more than those associated with medical conditions (Hedges g 0.76 vs 0.20, respectively). The aforementioned study corroborated a prior meta-analysis that studied 1379 adult patients with comorbid insomnia and found similar improvements in insomnia measures. 33 
Cautions
Certain components of CBTi should be avoided in patients with comorbidities. A meta-analysis found that a sleep abnormality was the most common prodrome inciting mania in patients with bipolar disorder and that sleep deprivation is associated with hypomania and mania. 34 Similarly, sleep loss is associated with an increase in daily manic symptoms. 34 Failure to decrease arousal or increasing arousal caused by the inability to sleep via SC measures could precipitate manic symptoms. SR could incite manic or hypomanic symptoms based on the aforementioned issues. In contrast, a small cohort of patients with bipolar disorder tolerated SC and SR (not deprivation) when closely monitored for sleepiness and increase in mood symptoms associated with mania or depression. 34 SR can result in decreased sleep time, increased daytime somnolence, and decreased reaction time and attentiveness during the acute phase of implementation. Kyle et al showed that these findings were most prominent during weeks 1 through 3 of CBTi implementation and that most patients returned to baseline values within 3 months. 35 As such, clinicians should counsel patients on the possible early adverse effects of CBTi that could have significant detrimental consequences and recommend monitoring intellectual and psychomotor readiness using the Epworth Sleepiness Scale before undertaking potentially dangerous tasks (eg, driving, operating heavy machinery).
Seizure disorders are a contraindication to SR because of the increased risk of inciting seizures via sleep deprivation. 36 Alternatively, SC is an acceptable option in the treatment of insomnia patients with epilepsy. 36 Initial weeks of SR therapy may cause excess daytime somnolence in patients with obstructive sleep apnea and hence may be contraindicated if not closely monitored as mentioned above. 37 Insomnia that develops as a result of positive airway pressure treatment in obstructive sleep apnea can be treated successfully with CBTi. 37 
Application in Primary Care Settings
The availability of trained psychologists limits the practical delivery of CBTi. This limitation has led several authors to explore self-help, Internet, and abbreviated delivery methods as well as nurse-administered CBTi. [38] [39] [40] A 2015 meta-analysis of 20 RCTs (N = 2411) to evaluate self-help CBT for insomnia demonstrated improvement in SE, SOL, and WASO. 38 These interventions included a variety of methodologies, including written, audiovisual, and Internet-based multimedia, and telephone contact augmentation. The interventions that included telephone contact with therapists showed improved efficacy.
Small-group-administered CBTi (<10 participants) is another treatment delivery option. A single-blind randomized study demonstrated that two 25-minute CBTi sessions delivered 2 weeks apart by a behavioralist in a primary care setting was more efficacious than typical SH instruction alone. 39 Similarly, an RCT conducted in Scotland (N = 201) compared a five-session, nurse-delivered CBTi intervention with typical care by general practitioners. 40 SE, SOL, and WASO improved up to 6 months posttreatment. In addition, nurse-facilitated group CBTi for adult patients led to a significant decrease in Mean Insomnia Severity Index scores and hypnotic use as well as significant improvements in all sleep variables when compared with controls. 41 The integration of behavioral health providers into primary care settings has proven to be a successful and efficient way to begin behavioral treatments for numerous mental health conditions. 42 These providers generally are clinical psychologists or social workers who can be consulted at the time that psychological conditions are discovered. In addition, these behavioral health consultants can teach CBT methods to primary care clinicians over time, thereby increasing access. Online and in-person training options exist for clinicians to enhance the ability of midlevel practitioners to deliver CBTi effectively in the primary care setting. 43 
Conclusions
CBTi is efficacious in numerous populations without significant adverse effects. Even so, widespread access to training for clinicians and patient-based limitations stand in the way of CBTi becoming a common therapeutic option. Further research must be conducted to develop time-efficient CBTi delivery methods to effectively care for patients with insomnia and avoid high-risk sedative use. 
